Hans Hammers, MD, PhD, discusses the efficacy of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Hans Hammers, MD, PhD, an associate professor of internal medicine in the Division of Hematology-Oncology at The University of Texas Southwestern Medical Center, discusses the efficacy of lenvatinib (Lenvima) plus pembrolizumab (Keytruda) in patients with advanced renal cell carcinoma (RCC).
The majority PD-1 or PD-L1 TKI combinations have historically yielded response rates of approximately 60%, with modest complete response (CR) rates, and a median progression-free survival (PFS) of approximately 15 to 16 months, according to Hammers.
However, data from the phase 3 CLEAR trial (NCT02811861) indicated that the combination of lenvatinib and pembrolizumab led to a median PFS of 23.9 months. The response rate with the doublet was 71%, with a CR rate of 16.1%, Hammers explains.
The trial provides a strong dataset and has identified another interesting treatment combination for patients with RCC, Hammers concludes.